Status: Recruiting
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Participants needed: 260
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Genentech, Inc.Updated: Jun 9, 2026Locations: 89
Eligibility criteria
Histologically confirmed diagnosis of PDAC [+9]
Prior adjuvant, neoadjuvant, or induction treatment for pancreatic cancer [+9]